Patents by Inventor Nandini Kashyap

Nandini Kashyap has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8637458
    Abstract: A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24 hours.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: January 28, 2014
    Assignee: Biodel Inc.
    Inventors: Roderike Pohl, Nandini Kashyap, Robert Hauser, Koray Ozhan, Solomon S. Steiner
  • Publication number: 20110281790
    Abstract: A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a period of 12 to 24 hours.
    Type: Application
    Filed: May 12, 2010
    Publication date: November 17, 2011
    Inventors: Roderike Pohl, Nandini Kashyap, Robert Hauser, Koray Ozhan, Solomon S. Steiner
  • Publication number: 20100069292
    Abstract: A clear basal insulin formulation composed of insulin (preferably human recombinant insulin), buffering agents, precipitating agents, and/or stabilizing agents for subcutaneous, intradermal or intramuscular administration.
    Type: Application
    Filed: September 2, 2009
    Publication date: March 18, 2010
    Inventors: Roderike Pohl, Nandini Kashyap, Robert Hauser, Koray Ozhan, Solomon S. Steiner
  • Publication number: 20090175840
    Abstract: Injectable insulin formulations that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these formulations are described herein. The formulation may be administered via subcutaneous, intradermal or intramuscular administration. In one preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin, an oxidizing agent or enzyme and a reducing agent or enzyme, a diluent and optionally one or more thickening agents. If a thickening agent is present in the formulation, the thickening agent increases the viscosity of the formulation following administration. Preferably the formulation contains an insulin, a diluent, glucose oxidase and peroxidase. Following administration to a patient, the insulin is released from the formulations as a function of the patient's tissue glucose level, which in turn maintains the patient's blood glucose level within an optimum range.
    Type: Application
    Filed: January 5, 2009
    Publication date: July 9, 2009
    Inventors: Nandini Kashyap, Solomon S. Steiner, Roderike Pohl